Skip to main content
Log in

Valaciclovir for Chronic Hepatitis B Virus Infection after Lung Transplantation

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract.

We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Speich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laube, I., Boehler, A., Renner, E.L. et al. Valaciclovir for Chronic Hepatitis B Virus Infection after Lung Transplantation. Infection 32, 51–53 (2004). https://doi.org/10.1007/s15010-003-3094-5

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-003-3094-5

Keywords

Navigation